Current Report Filing (8-k)
December 11 2019 - 4:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 6, 2019
Hancock
Jaffe Laboratories, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38325
|
|
33-0936180
|
(State or other
jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification
No.)
|
70
Doppler
Irvine,
California 92618
(Address
of principal executive offices) (Zip Code)
(949)
261-2900
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, par
value $0.00001 per share
|
|
HJLI
|
|
The NASDAQ Stock
Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
December 6, 2019, Hancock Jaffe Laboratories, Inc. (the “Company”) completed its 2019 annual meeting of stockholders
(the “Annual Meeting”). The number of shares of stock entitled to vote at the Annual Meeting was 17,922,129 shares
of common stock (the “Voting Stock”). The number of shares of Voting Stock present or represented by valid proxy at
the Annual Meeting was 11,306,644 shares. At the Annual Meeting, the Company’s stockholders (i) elected Mr. Matthew M. Jenusaitis
and Mr. Robert Berman as Class II directors and (ii) ratified the appointment of Marcum LLP as the Company’s independent
registered public accounting firm for the fiscal year ending December 31, 2019. The following is a tabulation of the voting on
the proposals presented at the Annual Meeting:
Proposal
No. 1 – Election of Class II directors
Mr.
Matthew M. Jenusaitis and Mr. Robert Berman were elected as Class II directors to serve for a three-year term that expires at
the 2022 annual meeting of stockholders or until their successors are elected and qualified or until their earlier death, incapacity,
removal or resignation. The voting results were as follows:
Nominee
|
|
Shares Voted For
|
|
Shares Withheld
|
|
Broker Non-Vote
|
Matthew M. Jenusaitis
|
|
7,233,102
|
|
329,589
|
|
3,743,953
|
Robert Berman
|
|
2,320,086
|
|
5,242,605
|
|
3,743,953
|
Proposal
No. 2 – Ratification of the appointment of independent registered public accounting firm
The
appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December
31, 2019 was ratified. The voting results were as follows:
Shares Voted For
|
|
Shares Voted Against
|
|
Shares Abstaining
|
|
Broker Non-Vote
|
11,036,600
|
|
54,103
|
|
215,941
|
|
0
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
HANCOCK JAFFE LABORATORIES,
INC.
|
|
|
Dated: December 11, 2019
|
/s/ Robert A. Berman
|
|
Robert A. Berman
|
|
Chief Executive Officer
|
Hancock Jaffe Laboratories (NASDAQ:HJLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hancock Jaffe Laboratories (NASDAQ:HJLI)
Historical Stock Chart
From Apr 2023 to Apr 2024